ProCE Banner Activity

CE / CME

Leveraging GLP-1 Receptor Agonist Options to Advance Glycemic Goals in Type 2 Diabetes

Text Module
Learn about the appropriate use of GLP-1 RAs to address elevated A1C, obesity, and CV risk, as well as strategies to improve tolerability and adherence.

Registered Nurses AANP : 1.00 AANP contact {hour}

Physicians : maximum of 1.00 AMA PRA Category 1 {Credit}

Released: July 13, 2020

Expiration: July 12, 2021

No longer available for credit.

Share

Faculty

John Russell

John Russell, MD

Clinical Professor
Department of Family and Community Medicine
Thomas Jefferson University
Sidney Kimmel Medical College
Philadelphia, Pennsylvania
Program Director
Family Medicine Residency Program
Abington Hospital
Abington, Pennsylvania

Neil Skolnik

Neil Skolnik, MD

Professor of Family and Community Medicine
Sidney Kimmel Medical College
Thomas Jefferson University
Philadelphia, Pennsylvania
Associate Director
Family Medicine Residency Program
Abington Jefferson Health
Abington, Pennsylvania

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Novo Nordisk Inc

Target Audience

Primary Care Providers

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Examine the evidence that supports the use of GLP-1 RA products in patients with T2D regarding their impact on weight and CV risk
  • Summarize the latest findings on renal outcomes from recent studies of GLP-1 RA products and implications for drug selection in patients at increased risk for nephropathy due to T2D
  • Differentiate the pharmacokinetic and pharmacodynamic characteristics of long-acting injection and emerging oral GLP-1 RA products and how to optimize their use early in the T2D disease course
  • Explore strategies to help patients prevent or overcome gastrointestinal adverse events and to improve rates of adherence with GLP-1 RA therapy

Faculty Disclosure

Primary Author

John Russell, MD

Clinical Professor
Department of Family and Community Medicine
Thomas Jefferson University
Sidney Kimmel Medical College
Philadelphia, Pennsylvania
Program Director
Family Medicine Residency Program
Abington Hospital
Abington, Pennsylvania

John Russell, MD, has disclosed the following financial relationships: Consultant: Sanofi Pasteur, GlaxoSmithKline Speaker: Sanofi Pasteur

Neil Skolnik, MD

Professor of Family and Community Medicine
Sidney Kimmel Medical College
Thomas Jefferson University
Philadelphia, Pennsylvania
Associate Director
Family Medicine Residency Program
Abington Jefferson Health
Abington, Pennsylvania

Neil Skolnik, MD, has disclosed the following financial relationships: Advisory Board Member: AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, GlaxoSmithKline, Intarcia Therapeutics, Inc., Janssen, Merck & Co., Inc., Mylan, Sanofi Pasteur, and Teva Research: AstraZeneca, Boehringer Ingelheim, and Sanofi Speaker: AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, and GlaxoSmithKline

Staff Disclosure

Staff

Jenny Schulz, PhD

Associate Managing Editor, Hepatitis
Clinical Care Options, LLC

Jenny Schulz, PhD, has no relevant conflicts of interest to report.

Zachary Schwartz, MSc, ELS

Scientific Director

Zachary Schwartz, MSc, ELS, has no relevant conflicts of interest to report.

Carolyn Skowronski, PharmD

Associate Director, Scientific Services

Carolyn Skowronski, PharmD, has no relevant conflicts of interest to report.

Instructions for Credit

Accreditation Statement

The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement

The National Association for Continuing Education designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The National Association for Continuing Education is approved as a provider of nurse practitioner continuing education by the American Association of Nurse Practitioners. AANP Provider Number 121222. This program has been approved for 1.0  contact hour of continuing education which includes 0.75 pharmacology hours.

Additional Information

Program Medium

This program has been made available online.